tert-butyl (R)-2-(1-((4-chloro-2,5-dimethylphenyl)sulfonyl)-3-oxo-1,2,3,4-tetrahydropyrazin-2-yl)acetate | 1372617-67-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: tert-butyl (R)-2-(1-((4-chloro-2,5-dimethylphenyl)sulfonyl)-3-oxo-1,2,3,4-tetrahydropyrazin-2-yl)acetate
• CAS: 1372617-67-8
• 化学式: C₁₈H₂₃ClN₂O₅S
• 分子量: 414.91
• InChiKey: DIVTYBMXOXDEPG-CQSZACIVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.65
• 重原子数：
  27.0
• 可旋转键数：
  4.0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  92.78
• 氢给体数：
  1.0
• 氢受体数：
  5.0

反应信息

• 作为反应物：
  描述：

  tert-butyl (R)-2-(1-((4-chloro-2,5-dimethylphenyl)sulfonyl)-3-oxo-1,2,3,4-tetrahydropyrazin-2-yl)acetate 在 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三氟乙酸 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 生成 1,1-dimethylethyl (4S)-4-((((2R)-1-((4-chloro-2,5-dimethylphenyl)sulfonyl)-3-oxo-1,2,3,4-tetrahydro-2-pyrazinyl)acetyl)amino)-3,3-dimethyl-1-piperidinecarboxylate
  参考文献：
  名称：

  Discovery of dehydro-oxopiperazine acetamides as novel bradykinin B1 receptor antagonists with enhanced in vitro potency

  摘要：

  In a series of bradykinin B1 antagonists, we discovered that replacement of oxopiperazine acetamides with dehydro-oxopiperazine acetamides provided compounds with enhanced activity against the B1 receptor. The synthesis and SAR leading to potent analogs with reduced molecular weight will be discussed. (C) 2011 Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmcl.2011.11.112
• 作为产物：
  描述：

  tert-butyl (R)-3-((4-chloro-2,5-dimethylphenyl)sulfonamido)-4-((2,2-dimethoxyethyl)amino)-4-oxobutanoate 在 对甲苯磺酸 作用下， 以 1,4-二氧六环 为溶剂， 生成 tert-butyl (R)-2-(1-((4-chloro-2,5-dimethylphenyl)sulfonyl)-3-oxo-1,2,3,4-tetrahydropyrazin-2-yl)acetate
  参考文献：
  名称：

  Discovery of dehydro-oxopiperazine acetamides as novel bradykinin B1 receptor antagonists with enhanced in vitro potency

  摘要：

  In a series of bradykinin B1 antagonists, we discovered that replacement of oxopiperazine acetamides with dehydro-oxopiperazine acetamides provided compounds with enhanced activity against the B1 receptor. The synthesis and SAR leading to potent analogs with reduced molecular weight will be discussed. (C) 2011 Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmcl.2011.11.112